Today’s 437th FREE online 1Mby1M Roundtable For Entrepreneurs is starting NOW, on Thursday, March 28, at 8 a.m. PDT/11 a.m. EDT/4 p.m. CET/8:30 p.m. India IST. Click here to join. All are welcome!
Today’s 437th FREE online 1Mby1M Roundtable For Entrepreneurs is starting in 30 minutes, on Thursday, March 28, at 8 a.m. PDT/11 a.m. EDT/4 p.m. CET/8:30 p.m. India IST. Click here to join. All are welcome!
Sramana Mitra: You put in context what might happen with the existing workflow of the drug development as we introduce more capability from a scalability point of view. Instead of a drug going through three or four stages of clinical trials, maybe it will go through five or ten stages of clinical trials going into
Mark Selcow, General Partner at Costanoa Ventures, talks about the firm’s primarily B-to-B investment thesis and strong penchant for investing in companies that have grown up outside the Bay Area.
Sramana Mitra: If you get carried away and raise huge amounts of money, you better have a strategy of doing something that is going to get you to the right exit because all these investors also need exits and you need exits. This is a very complex set of strategic moves that you’re going to
Sramana Mitra: If you look at all the things that they’ve been doing and all the product roadmap announcements that they’ve made, they’re going into clinical trials in a big way. That’s why I asked you the question. Historically, they have come out of CRM but clinical research organizations and clinical trials has been one
Harald Nieder, Partner at Redalpine Venture Partners, an European firm primarily focused on Germany and Switzerland.
Entrepreneurs are invited to the 437th FREE online 1Mby1M mentoring roundtable on Thursday, March 28, 2019, at 8 a.m. PDT/11 a.m. EDT/4 p.m. CET/8:30 p.m. India IST. If you are a serious entrepreneur, register to “pitch” and sell your business idea. You’ll receive straightforward feedback, advice on next steps, and answers to any of your questions. Others